Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
Donia M. Moujalled, Fiona C. Brown, Chong Chyn Chua, et al.
Blood (2022) Vol. 141, Iss. 6, pp. 634-644
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Mechanisms of BCL-2 family proteins in mitochondrial apoptosis
Peter E. Czabotar, Ana J. García‐Sáez
Nature Reviews Molecular Cell Biology (2023) Vol. 24, Iss. 10, pp. 732-748
Closed Access | Times Cited: 255
Leukemic stem cells and therapy resistance in acute myeloid leukemia
Patrick Stelmach, Andreas Trumpp
Haematologica (2023) Vol. 108, Iss. 2, pp. 353-366
Open Access | Times Cited: 97
Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy
Jiuyang Liu, Shuran Li, Qin Wang, et al.
Blood (2024) Vol. 143, Iss. 18, pp. 1825-1836
Open Access | Times Cited: 26
Multi-omics advances for molecular characterization, precision medicine, and prognostic implications in leukemia
Shangyu Hou, Junya Liu, Yinghui Zhu
Cell investigation. (2025) Vol. 1, Iss. 1, pp. 100007-100007
Open Access | Times Cited: 2
Venetoclax resistance: mechanistic insights and future strategies
Faustine Ong, Kunhwa Kim, Marina Konopleva
Cancer Drug Resistance (2022) Vol. 5, Iss. 2, pp. 380-400
Open Access | Times Cited: 61
Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths
Mariela Cortés-López, Paulina Chamely, Allegra G. Hawkins, et al.
Cell stem cell (2023) Vol. 30, Iss. 9, pp. 1262-1281.e8
Open Access | Times Cited: 32
Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1656-1677
Open Access | Times Cited: 29
Chemical modulation of cytosolic BAX homodimer potentiates BAX activation and apoptosis
Nadege Gitego, Bogos Agianian, Oi Wei Mak, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 23
AML treatment: conventional chemotherapy and emerging novel agents
Mark Forsberg, Marina Konopleva
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 5, pp. 430-448
Closed Access | Times Cited: 13
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers
Sarah T. Diepstraten, Yuan Yin, John E. La Marca, et al.
Cancer Cell (2024) Vol. 42, Iss. 5, pp. 850-868.e9
Open Access | Times Cited: 12
Venetoclax Resistance in Acute Myeloid Leukemia
Sylvain Garciaz, Marie‐Anne Hospital, Yves Collette, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1091-1091
Open Access | Times Cited: 9
Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights
Boaz Nachmias, Shlomzion Aumann, Arnon Haran, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 4, pp. 1146-1158
Open Access | Times Cited: 8
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Gus O. Nwosu, David M. Ross, Jason A. Powell, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 8
The medicinal chemistry of piperazines: A review
Md Imam Faizan, Rajnish Kumar, Avijit Mazumder, et al.
Chemical Biology & Drug Design (2024) Vol. 103, Iss. 6
Closed Access | Times Cited: 8
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
Bing Z. Carter, Po Yee Mak, Wenjing Tao, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 17
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance
Nils Wellhausen, Joanne Seoyoung Baek, Saar Gill, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 9, pp. 614-628
Closed Access | Times Cited: 7
BCL-2 inhibition in haematological malignancies: Clinical application and complications
Dominic Fowler-Shorten, Charlotte Hellmich, Matthew Markham, et al.
Blood Reviews (2024) Vol. 65, pp. 101195-101195
Closed Access | Times Cited: 6
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia
Ellen Madarang, Jill Lykon, Wei Zhao, et al.
Deleted Journal (2024) Vol. 1, Iss. 2, pp. 100016-100016
Open Access | Times Cited: 6
The C-terminal sequences of Bcl-2 family proteins mediate interactions that regulate cell death
Dang Nguyen, Elizabeth J. Osterlund, Justin Kale, et al.
Biochemical Journal (2024) Vol. 481, Iss. 14, pp. 903-922
Open Access | Times Cited: 6
Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs
Sarah T. Diepstraten, Savannah Young, John E. La Marca, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 4, pp. 1005-1017
Open Access | Times Cited: 14
BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond
Andrew H. Wei, Andrew W. Roberts
HemaSphere (2023) Vol. 7, Iss. 6, pp. e912-e912
Open Access | Times Cited: 13
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
Stephen K. Tahir, Emiliano Calvo, Benedito A. Carneiro, et al.
Blood (2023) Vol. 141, Iss. 17, pp. 2114-2126
Open Access | Times Cited: 11
Venetoclax and beyond: New Horizons in CLL and AML therapy
Matteo Molica, Salvatore Perrone
Expert Review of Anticancer Therapy (2025)
Closed Access
Differential regulation of BAX and BAK apoptotic activity revealed by small molecules
Kaiming Li, Yu Q. Yap, Donia M. Moujalled, et al.
Science Advances (2025) Vol. 11, Iss. 10
Open Access
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Meike Vogler, Yannick Braun, Victoria M. Smith, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top